Terms: = Thyroid cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Prognosis
6 results:
1. Targeting nrf2 to treat thyroid cancer.
Gong Z; Xue L; Li H; Fan S; van Hasselt CA; Li D; Zeng X; Tong MCF; Chen GG
Biomed Pharmacother; 2024 Apr; 173():116324. PubMed ID: 38422655
[TBL] [Abstract] [Full Text] [Related]
2. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract] [Full Text] [Related]
3. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
4. Pan-cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many cancers.
Qureshi MA; Khan S; Tauheed MS; Syed SA; Ujjan ID; Lail A; Sharafat S
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3199-3209. PubMed ID: 33247676
[TBL] [Abstract] [Full Text] [Related]
5. Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma.
Noda M; Okumura H; Uchikado Y; Omoto I; Sasaki K; Kita Y; Mori S; Owaki T; Arigami T; Uenosono Y; Nakajo A; Kijima Y; Ishigami S; Maemura K; Natsugoe S
Ann Surg Oncol; 2018 Feb; 25(2):449-455. PubMed ID: 29188501
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (nrf2) expression in gastric cancer.
Kawasaki Y; Ishigami S; Arigami T; Uenosono Y; Yanagita S; Uchikado Y; Kita Y; Nishizono Y; Okumura H; Nakajo A; Kijima Y; Maemura K; Natsugoe S
BMC Cancer; 2015 Jan; 15():5. PubMed ID: 25588809
[TBL] [Abstract] [Full Text] [Related]
